Literature DB >> 26091565

Management of low- and intermediate-risk prostate cancer.

Henk van der Poel1, Laurence Klotz, Christian G Stief.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26091565     DOI： 10.1007/s00345-015-1618-0

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  9 in total

1.  Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).

Authors:  Ekaterina Lellig; Christian Gratzke; Alexander Kretschmer; Christian Stief
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

2.  Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice.

Authors:  Andrea Billing; Alexander Buchner; Christian Stief; Alexander Roosen
Journal:  World J Urol       Date:  2014-11-29       Impact factor: 4.226

3.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

4.  The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence.

Authors:  A Karl; A Buchner; C Tympner; T Kirchner; U Ganswindt; C Belka; R Ganzer; M Burger; F Eder; F Hofstädter; D Schilling; K Sievert; A Stenzl; M Scharpf; F Fend; F Vom Dorp; H Rübben; K Schmid; D Porres-Knoblauch; A Heidenreich; B Hangarter; R Knüchel-Clarke; M Rogenhofer; B Wullich; A Hartmann; E Comploj; A Pycha; E Hanspeter; D Pehrke; G Sauter; M Graefen; C Stief; A Haese
Journal:  World J Urol       Date:  2015-02-15       Impact factor: 4.226

Review 5.  Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Authors:  Raphaele Renard-Penna; Geraldine Cancel-Tassin; Eva Comperat; Morgan Roupret; Pierre Mozer; Olivier Cussenot
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

6.  Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.

Authors:  Souhil Lebdai; Arnaud Villers; Eric Barret; Cosmina Nedelcu; Pierre Bigot; Abdel-Rahmène Azzouzi
Journal:  World J Urol       Date:  2015-01-23       Impact factor: 4.226

7.  TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.

Authors:  A R Azzouzi; E Barret; J Bennet; C Moore; S Taneja; G Muir; A Villers; J Coleman; C Allen; A Scherz; M Emberton
Journal:  World J Urol       Date:  2015-02-25       Impact factor: 4.226

Review 8.  Histological outcomes after focal high-intensity focused ultrasound and cryotherapy.

Authors:  Taimur T Shah; Veeru Kasivisvanathan; Charles Jameson; Alex Freeman; Mark Emberton; Hashim U Ahmed
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

9.  Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

Authors:  Abdel-Rahmene Azzouzi; Souhil Lebdai; Fawzi Benzaghou; Christian Stief
Journal:  World J Urol       Date:  2015-03-19       Impact factor: 4.226
  9 in total
  1 in total

1.  miR-301a expression: A prognostic marker for prostate cancer.

Authors:  Chendil Damodaran; Trinath P Das; A M Sashi Papu John; Suman Suman; Venkatesh Kolluru; Targhee J Morris; Erin N Faber; Shesh N Rai; Jamie C Messer; Houda Alatassi; Murali K Ankem
Journal:  Urol Oncol       Date:  2016-04-26       Impact factor: 3.498
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.